SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4584-4587. Prepublished online as a Blood First Edition Paper on September 7, 2007; DOI 10.1182/blood-2007-07-101071. This Article Full Text (PDF) All Versions of this Article: blood-2007-07-101071v1 110/13/4584    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Frangoul, H. Articles by Grupp, S. A Search for Related Content PubMed PubMed Citation Articles by Frangoul, H. Articles by Grupp, S. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 13, 2007 Accepted August 25, 2007 A prospective study of G-CSF primed bone marrow as a stem cell course for allogeneic bone marrow transplant in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study Haydar Frangoul*, Eneida R Nemecek, Dean Billheimer, Michael A Pulsipher, Shakila Khan, Ann Woolfrey, Becky Manes, Catherine Cole, Mark C Walters, Mouhab Ayas, Yaddanapudi Ravindranath, John E Levine, and Stephan A Grupp Vanderbilt University, Nashville, TN, United States Oregon Health & Science University, Portland, OR, United States Primary Children's Medical Center, University of Utah, Salt Lake City, UT, United States Mayo Clinic, Rochester, MN, United States Fred Hutchinson Cancer Center, Seattle, WA, United States Princess Margaret Hospital for Children, Perth, Australia Children's Hospital Oakland & Research Center, Oakland, CA, United States King Faisal Medical Center, Riyadh, Saudi Arabia Wayne State University, Detroit, MI, United States University of Michigan, Ann Arbor, MI, United States Children's Hospital of Philadelphia, Philadelphia, PA, United States * Corresponding author; email: haydar.frangoul{at}vanderbilt.edu. A prospective multi-center trial was conducted to evaluate the safety and feasibility of granulocyte-colony stimulating factor primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). Forty two children with a median age of 9.8 years (range 0.8-17) were enrolled. Donors with median age of 9.2 y (range 1.1-22) received 5 mcg/kg/day of subcutaneous G-CSF for 5 consecutive days. Bone marrow was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7x108/kg (range 2.4-18.5) and 7.4x106/kg (range 2-27.6) respectively. Neutrophil and platelet engraftment was at a median of 19 days (13-28), and 20 days (9-44) respectively. Thirteen patients (32%) developed grade II graft-versus-host disease (GVHD) and 5 of 40 evaluable patients (13%) developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event free survival at 2 years were 81% and 69% respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020